175 related articles for article (PubMed ID: 29522570)
1. Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.
Vlot MC; Grijsen ML; Prins JM; de Jongh RT; de Jonge R; den Heijer M; Heijboer AC
PLoS One; 2018; 13(3):e0193679. PubMed ID: 29522570
[TBL] [Abstract][Full Text] [Related]
2. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
Kwak MK; Lee EJ; Park JW; Park SY; Kim B-; Kim TH; Suh K; Koh J-; Lee SH; Byun D-
Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
[TBL] [Abstract][Full Text] [Related]
3. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
[TBL] [Abstract][Full Text] [Related]
4. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
6. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
Bloch M; Tong WW; Hoy J; Baker D; Lee FJ; Richardson R; Carr A;
HIV Med; 2014 Jul; 15(6):373-80. PubMed ID: 24460797
[TBL] [Abstract][Full Text] [Related]
7. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
8. Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.
Zhang L; Su Y; Hsieh E; Xia W; Xie J; Han Y; Cao Y; Li Y; Song X; Zhu T; Li T; Yu W
BMC Musculoskelet Disord; 2013 Jul; 14():224. PubMed ID: 23899016
[TBL] [Abstract][Full Text] [Related]
9. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
[TBL] [Abstract][Full Text] [Related]
10. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.
Vlot MC; Klink DT; den Heijer M; Blankenstein MA; Rotteveel J; Heijboer AC
Bone; 2017 Feb; 95():11-19. PubMed ID: 27845262
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P;
PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of reduced bone mineral density in primary HIV-1-infected men.
Grijsen ML; Vrouenraets SM; Steingrover R; Lips P; Reiss P; Wit FW; Prins JM
AIDS; 2010 Sep; 24(14):2233-8. PubMed ID: 20616695
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis and osteopenia are not associated with T-cell activation in older cART-treated HIV-infected patients.
Krikke M; Klomberg RCW; van der Veer E; Tesselaar K; Verhaar HJJ; Hoepelman AIM; Arends JE
Neth J Med; 2017 May; 75(4):138-144. PubMed ID: 28522769
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of bone density in human immunodeficiency virus-infected women.
Dolan SE; Kanter JR; Grinspoon S
J Clin Endocrinol Metab; 2006 Aug; 91(8):2938-45. PubMed ID: 16735489
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral-naïve HIV-infected patients had lower bone formation markers than HIV-uninfected adults.
Wattanachanya L; Jantrapakde J; Avihingsanon A; Ramautarsing R; Kerr S; Trachunthong D; Pussadee K; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Phanuphak N; Sunthornyothin S; Phanuphak P;
AIDS Care; 2020 Aug; 32(8):984-993. PubMed ID: 31137948
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
Roberts J; Castro C; Moore AE; Fogelman I; Hampson G
Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
[TBL] [Abstract][Full Text] [Related]
19. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
Carr A; Kerr SJ; Richardson R; Ebeling P; Pocock N; Rojas J; Martinez E; Hoy J;
J Bone Miner Res; 2019 Dec; 34(12):2192-2197. PubMed ID: 31361922
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
